Faculty of Science
Kathleen Prosser receives Vanier Canada Graduate Scholarship
Kathleen is working to improve upon current chemotherapeutic treatments of cancer which are limited by acquired resistance, a small range of activity and high toxicity. Through the synthesis of new compounds, and a careful examination of their fundamental chemical behaviour, these issues can be addressed at a molecular level. Her research aims to achieve these goals by improving upon current therapies through the incorporation of inorganic components. An example of a previous success in this area is the drug Ferrocifen. Ferrocifen is a chemotherapeutic that significantly increased the efficacy of the breast cancer treatment Tamoxifen through the incorporation of an iron group (ferrocene).
With this success as inspiration, her research focuses on the functionalization of other approved chemotherapies with metals. Chemical, biochemical and biological studies will offer insight into relationships between the fundamental chemical properties and the biological activity of these functionalized compounds. With this knowledge, complexes with maximum efficacy as potential anticancer agents can be determined and the understanding of trends will allow for continued improvement.
Kathleen has shown a remarkable talent for not only conducting research and publication, but for taking on leadership roles in her lab as well as in her department. She is committed to mentoring undergraduate students and remaining engaged with the department at large through involvement with the Graduate Caucus and science outreach.
Kathleen Prosser is one of six students at SFU in 2014/15 to receive a Vanier Canada Graduate Scholarship, which are granted to graduate students studying in Canada based on their academic excellence, research potential, and leadership contributions.
For more information or to connect with Kathleen see: